Overexpression of NANOG, SOX2 and OCT4 have been linked to therapy resistance, reduced overall survival and increased progression in ovarian cancer, head and neck, breast, renal and rectal cancer patients [91,98,99,100,101,102,103,104]. The gene discussed is NANOG; the disease is ovarian cancer.